Abstract
Orally administered adenovirus may be a useful vaccine carrier of cloned antigens of other pathogens. A recombinant adenohepatitis vaccine Wy-Ad7HZ6-1, which expressed hepatitis B surface antigen and contained a large deletion in early region 3 (E3), was constructed and studied in humans. Volunteers received Wy-Ad7HZ6-1 (n = 3), adenovirus type 7 vaccine (n = 3) or placebo (n = 3). Recipients of Wy-Ad7HZ6-1 shed less vaccine virus in the stool for a shorter period and had a lower titre of anti-adenovirus type 7 antibodies than recipients of the adenovirus 7 vaccine. None of the three Wy-Ad7HZ6-1 vaccinees developed antibody to hepatitis B surface antigen after this one dose primary immunization regimen. The E3 region may be required for optimal enteric growth of adenovirus-vectored vaccines.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adenoviruses, Human / immunology*
-
Adenoviruses, Human / isolation & purification
-
Administration, Oral
-
Adolescent
-
Adult
-
Antibodies, Viral / biosynthesis
-
Drug Evaluation
-
Hepatitis B Surface Antigens / immunology
-
Hepatitis B virus / immunology*
-
Hepatitis B virus / isolation & purification
-
Humans
-
Male
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / adverse effects*
-
Vaccines, Synthetic / immunology*
-
Viral Hepatitis Vaccines / administration & dosage
-
Viral Hepatitis Vaccines / adverse effects*
-
Viral Hepatitis Vaccines / immunology*
Substances
-
Antibodies, Viral
-
Hepatitis B Surface Antigens
-
Vaccines, Synthetic
-
Viral Hepatitis Vaccines